Janus Henderson Group
MRSN

Janus Henderson Group’s Mersana Therapeutics MRSN Stock Holding History

Janus Henderson Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,226
Closed -$38.8K – 2586
2023
Q3 		$38.8K Buy
1,226
+1
+0.1% +$48 ﹤0.01% 2553
2023
Q2 		$101K Sell
1,225
-1
-0.1% -$146 ﹤0.01% 2566
2023
Q1 		$126K Buy
1,226
+772
+170% +$108K ﹤0.01% 2591
2022
Q4 		$66.5K Hold
454
– – ﹤0.01% 2396
2022
Q3 		$77K Hold
454
– – ﹤0.01% 2087
2022
Q2 		$53K Buy
454
+6
+1% +$564 ﹤0.01% 2547
2022
Q1 		$45K Hold
448
– – ﹤0.01% 2623
2021
Q4 		$70K Buy
+448
New +$87.2K ﹤0.01% 2523
2021
Q1 		– Sell
-36,764
Closed -$24.5M – 1605
2020
Q4 		$24.5M Buy
36,764
+410
+1% +$228K 0.01% 710
2020
Q3 		$16.9M Buy
36,354
+34,059
+1,484% +$17.2M 0.01% 744
2020
Q2 		$1.34M Buy
+2,295
New +$784K ﹤0.01% 1089

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Janus Henderson Group's MRSN Position: Q4 2023 in Review

Janus Henderson Group sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 1,226 shares — an estimated $38.8K sold.

Janus Henderson Group first reported a position in MRSN in Q2 2020 and held it in 11 quarters. The position peaked at $24.5M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Janus Henderson Group reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Janus Henderson Group sold 1,226 Mersana Therapeutics shares in Q4 2023, an estimated $38.8K.
  • Janus Henderson Group first reported a position in Mersana Therapeutics in Q2 2020 and held it in 11 quarters.
  • Janus Henderson Group's Mersana Therapeutics position peaked at $24.5M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.